

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2792329

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MICHAL N. ARNON	01/30/2014
TATIANA KAMENETSKY	02/11/2014
RECEIVING PARTY DATA	
Name:	PERRIGO ISRAEL PHARMACEUTICALS LTD.
Street Address:	29 LEHI STREET
City:	BNEI BRAK
State/Country:	ISRAEL
Postal Code:	51200
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14233198
CORRESPONDENCE DATA	
Fax Number:	(937)443-6635
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	937-443-6600
Email:	ipdocket@thompsonhine.com
Correspondent Name:	MARK P. LEVY
Address Line 1:	10050 INNOVATION DRIVE
Address Line 2:	SUITE 400
Address Line 4:	DAYTON, OHIO 45342-4934
NAME OF SUBMITTER:	MARK P. LEVY
SIGNATURE:	/Mark P. Levy/
DATE SIGNED:	03/31/2014
Total Attachments: 1	
source=Assignment_Perrigo_Israel#page1.tif	

Application No. 14/233,198

Filed: _____



ASSIGNMENT

WHEREAS, **Michal N. Arnon**, of Midreshet Ben-Gurion, Israel, and **Tatiana Kamenetsky**, of Beer Sheva, Israel, invented a certain new and useful TOPICAL OILY FOAM COMPOSITIONS for which I/we executed an application for letters patent of the United States;


AND WHEREAS, **Perrigo Israel Pharmaceuticals Ltd.**, a corporation of Israel, with a place of business at 29 Lehi Street, Bnei Brak, 51200, Israel, hereinafter called the Assignee, is desirous of acquiring the entire right, title and interest in and to said application and the inventions therein disclosed and any letters patent that may issue thereon;

NOW, THEREFORE, in consideration of the sum of One Dollar (\$1.00) and other valuable consideration, receipt whereof is hereby acknowledged, I/we hereby sell, assign and transfer unto said Assignee, its successors and assigns, the entire right, title and interest in and to said application, any application claiming priority therefrom, any non-provisionals, divisions or continuations thereof, and the inventions therein disclosed, and any improvements thereon, and any patent or patents that may be issued or reissued thereon, and I/we hereby authorize and request the Commissioner of Patents and Trademarks to issue any letters patent thereon, and reissues thereof, to said Assignee, its successors and assigns; and I/we hereby authorize said Assignee, its successors and assigns, to file in its own name applications for patent in foreign countries in connection with the inventions hereby transferred, under the International Convention claiming the priority of said United States application or otherwise, and to secure in its own name the patent or patents issued thereon; and I/we hereby agree that, upon request, I/we will sign all papers, and make all rightful oaths, and do all acts which said Assignee, its successors or assigns, may consider necessary in connection with said United States application, and in connection with any other United States or foreign applications that may be filed in connection with said inventions, and with any improvements thereon, and in connection with any patents issued or reissued thereon.



The undersigned hereby grants Mark P. Levy, Registration No. 27922, of Thompson Hine, LLP, 10050 Innovation Drive, Suite 400, Dayton, Ohio, 45342-4934, power to insert in this assignment any further identification that may be necessary or desirable in order to aid in the recordation of this document.

Inventor Signature:  Date: Feb. 11, 2014
 Date: Jan. 30, 2014

Michal Arnon, B. Pharm
Formulation Team Leader

Witness Signature:  Date: Feb 11, 2014

Michal N. Arnon
Chaim Aschkenasy, Ph.D.
Formulation R&D Manager

Inventor Signature:  Date: Feb. 11, 2014


Tatiana Kamenetsky, M.S
Formulation Researcher

Witness Signature:  Date: Feb 11, 2014

Chaim Aschkenasy, Ph.D.
Formulation R&D Manager

765449.1